In this retrospective cohort study, we provided a preliminary picture on the long-term follow-up of combining anti-PD-1 with trastuzumab and chemotherapy in HER2-positive GC, although no statistically significant difference in PFS and OS was observed compared with the current standard. Here, ERBB2 is linked to gastric cancer.